Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER).


Ressource 1Download: 33934060_BIB_9B6A0DE80EF6.pdf (421.25 [Ko])
State: Public
Version: Final published version
License: Not specified
Serval ID
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER).
European journal of cancer
Tougeron D., Hentzien M., Seitz-Polski B., Bani-Sadr F., Bourhis J., Ducreux M., Gaujoux S., Gorphe P., Guiu B., Hoang-Xuan K., Huguet F., Lecomte T., Lièvre A., Louvet C., Maggiori L., Mansi L., Mariani P., Michel P., Servettaz A., Thariat J., Westeel V., Aparicio T., Blay J.Y., Bouché O.
Working group(s)
for Thésaurus National de Cancérologie Digestive (TNCD), réseau de Groupes Coopérateurs en Oncologie (GCO), Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER), Association de Chirurgie Hépato-Bilio-Pancréatique et Transplantation (ACHBT), Association de Recherche sur les Cancers Gynécologiques-Groupes d'Investigateurs Nationaux pour l'étude des Cancers Ovariens et du Sein (ARCAGY-GINECO), Fédération Francophone de Cancérologie Digestive (FFCD), Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR), Groupe d'Oncologie Radiothérapie Tête et Cou-Intergroupe ORL (GORTEC-Intergroupe ORL), Intergroupe Francophone de Cancérologie Thoracique (IFCT), InterGroupe Coopérateur de Neuro-Oncologie/Association des Neuro-Oncologues d'Expression Française (IGCNO-ANOCEF), Société Française de Chirurgie Digestive (SFCD), Société Française d'Endoscopie Digestive (SFED), Société Française de Radiothérapie Oncologique (SFRO), Société Française de Radiologie (SFR), Société Nationale Française de Colo-Proctologie (SNFCP), Société Nationale Française de Gastroentérologie (SNFGE)
1879-0852 (Electronic)
Publication state
Issued date
Publication types: Journal Article ; Review
Publication Status: ppublish
The impacts of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic on cancer care are multiple, entailing a high risk of death from coronavirus disease 2019 (COVID-19) in patients with cancer treated by chemotherapy. SARS-CoV-2 vaccines represent an opportunity to decrease the rate of severe COVID-19 cases in patients with cancer and also to restore normal cancer care. Patients with cancer to be targeted for vaccination are difficult to define owing to the limited contribution of these patients in the phase III trials testing the different vaccines. It seems appropriate to vaccinate not only patients with cancer with ongoing treatment or with a treatment having been completed less than 3 years ago but also household and close contacts. High-risk patients with cancer who are candidates for priority access to vaccination are those treated by chemotherapy. The very high-priority population includes patients with curative treatment and palliative first- or second-line chemotherapy, as well as patients requiring surgery or radiotherapy involving a large volume of lung, lymph node and/or haematopoietic tissue. When possible, vaccination should be carried out before cancer treatment begins. SARS-CoV-2 vaccination can be performed during chemotherapy while avoiding periods of neutropenia and lymphopenia. For organisational reasons, vaccination should be performed in cancer care centres with messenger RNA vaccines (or non-replicating adenoviral vaccines in non-immunocompromised patients). Considering the current state of knowledge, the benefit-risk ratio strongly favours SARS-CoV-2 vaccination of all patients with cancer. To obtain more data concerning the safety and effectiveness of vaccines, it is necessary to implement cohorts of vaccinated patients with cancer.
COVID-19/prevention & control, COVID-19 Vaccines/therapeutic use, Humans, Neoplasms/complications, SARS-CoV-2, COVID-19, Chemotherapy, Coronavirus, Radiotherapy, Solid cancers, Vaccination
Web of science
Open Access
Create date
19/05/2021 13:20
Last modification date
25/01/2024 8:41
Usage data